ABBOTT, F. M., 2016, « Excessive Pharmaceutical Prices and Competition Law: Doctrinal Development to Protect Public Health », UC Irvine Law Review, vol. 6, p. 281.
ABRAHAM, J., 1995, Science, politics and the pharmaceutical industry: Controversy and bias in drug regulation, UCL Press.
ABRAHAM, J., 2002, « The pharmaceutical industry as a political player », The Lancet, vol. 360, n° 9344, p. 1498‑1502.
ABRAHAM, J., REED, T., 2010, « Trading risks for markets: The international harmonisation of pharmaceuticals regulation », Health, Risk & Society, En ligne : https://www.tandfonline.com/doi/abs/10.1080/713670172.
ADELMAN, M. J., BALDIA, S., 1996, « Prospects and Limits of the Patent Provision in the TRIPS Agreement: The Case of India », Vanderbilt Journal of Transnational Law, vol. 29, p. 507.
ATHREYE, S., GODLEY, A., 2009, « Internationalization and technological leapfrogging in the pharmaceutical industry », Industrial and Corporate Change, vol. 18, n° 2, p. 295‑323.
BANERJEE, D., 2017, « Markets and Molecules: A Pharmaceutical Primer from the South », Medical Anthropology, vol. 36, n° 4, p. 363‑380.
BAXERRES, C., 2011, « Why is there an informal market of pharmaceuticals in French-speaking countries of West Africa ? », Politique africaine, vol. 123, n° 3, p. 117‑136.
BOURGAIN, C., CASSIER, M., GAUDILLIERE, J.-P., JUVEN, P.-A., 2021, « Les félicités du capital en santé », Revue française de socio-Economie, n° 1, p. 127‑147.
BOURGERON, T., GEIGER, S., 2022, « (De-)assetizing pharmaceutical patents: Patent contestations behind a blockbuster drug », Economy and Society, vol. 51, n° 1, p. 23‑45.
BRHILIKOVA, P., POLLOCK, A., BASU, S., BHATTARAI, S., GUPTA, A. D., SINGH, N., et al., 2007, « Good manufacturing practice in the pharmaceutical industry »,
BRHLIKOVA, P., HARPER, I., JEFFERY, R., RAWAL, N., SUBEDI, M., SANTHOSH, M., 2011, « Trust and the regulation of pharmaceuticals: South Asia in a globalised world », Globalization and Health, vol. 7, n° 1, p. 2‑13.
CASSIER, M., 2008, « Brevets pharmaceutiques et acces aux médicaments: Inventer de nouvelles solutions », Technology review.
CASSIER, M., 2019, « La fin du partage? Les capitalismes de la copie face au capitalisme de la rente globale: une nouvelle géographie des industries de santé », Mouvements, n° 2, p. 107‑119.
CASSIER, M., 2021, « Value regimes and pricing in the pharmaceutical industry: financial capital inflation (hepatitis C) versus innovation and production capital savings for malaria medicines », BioSocieties, vol. 16, n° 3, p. 323‑341.
CHAUDHURI, S., 1984, « Manufacturing Drugs without TNCs », Economic & Political Weekly, vol. 19, n° 33, p. 1341‑1383.
CHAUDHURI, S., 2015, « Pharmaceutical prices in India », in Pharmaceutical prices in the 21st century, Springer, p. 113‑130
CHAUDHURI, S., 2021, « How Effective Are Government Measures to Control Prices of Anticancer Medicines in India? », Economic & Political Weekly, vol. 56, n° 22, p. 49.
CHITTOOR, R., RAY, S., AULAKH, P. S., SARKAR, M. B., 2008, « Strategic responses to institutional changes: ‘Indigenous growth’ model of the Indian pharmaceutical industry », Journal of International Management, vol. 14, n° 3, p. 252‑269.
CHOREV, N., 2012, « Changing Global Norms through Reactive Diffusion: The Case of Intellectual Property Protection of AIDS Drugs », American Sociological Review, vol. 77, n° 5, p. 831‑853.
COOL, K. O., SCHENDEL, D., 1987, « Strategic Group Formation and Performance: The Case of the U.S. Pharmaceutical Industry, 1963–1982 », Management Science, vol. 33, n° 9, p. 1102‑1124.
DAS GUPTA, C., 2016a, State and Capital in Independent India: Institutions and Accumulations, Cambridge University Press.
DAS GUPTA, C., 2016b, « ‘Old Oligopolies and New Entrants’ in the Pharmaceutical Sector », in State and Capital in Independent India: Institutions and Accumulations, Cambridge University Press, p. 218‑256
DAVIS, C., ABRAHAM, J., 2013, Unhealthy pharmaceutical regulation: Innovation, politics and promissory science, Springer.
EREN-VURAL, I., 2007, « Domestic contours of global regulation: Understanding the policy changes on pharmaceutical patents in India and Turkey », Review of International Political Economy, vol. 14, n° 1, p. 105‑142.
GAMBA, S., PERTILE, P., VOGLER, S., 2020, « The impact of managed entry agreements on pharmaceutical prices », Health Economics, vol. 29, n° S1, p. 47‑62.
GAUDILLIERE, J., 2008, « How pharmaceuticals became patentable: the production and appropriation of drugs in the twentieth century », History and Technology, vol. 24, n° 2, p. 99‑106.
GEIGER, S., FINCH, J., 2016, « Promissories and pharmaceutical patents: agencing markets through public narratives », Consumption Markets & Culture, vol. 19, n° 1, p. 71‑91.
GUENNIF, S., 2013, « L’économie politique du brevet au Sud : dimensions industrielle et sanitaire: », Mondes en développement, vol. n°160, n° 4, p. 85‑98.
GUERIN, P. J., SINGH-PHULGENDA, S., STRUB-WOURGAFT, N., 2020, « The consequence of COVID-19 on the global supply of medical products: Why Indian generics matter for the world? », F1000Research, En ligne : https://f1000research.com/articles/9-225/v1.
HAURAY, B., 2007, « Les laboratoires pharmaceutiques et la construction d’une régulation européenne des médicaments », Revue française des affaires sociales, vol. 1, n° 3, p. 233.
HENSMAN, R., 2014, « The Gujarat model of development », Economic and Political Weekly.
HIRSCHMAN, A. O., 1970, Exit, voice, and loyalty: responses to decline in firms, organizations, and states, Cambridge, Mass, Harvard Univ. Press.
HIRWAY, I., SHAH, A., SHAH, G. (Éd.), 2014, Growth or development: which way is Gujarat going?, New Delhi, Oxford University Press.
IMMEL, B. K., 2001, « A brief history of the GMPs for pharmaceuticals », Pharmaceutical technology, vol. 25, n° 7, p. 44‑53.
IYER, P. K., 2008, Structure and Performance of Small and Medium Scale Pharmaceutical Firms, Rochester, NY, Social Science Research Network.
IYER, P. K., 2016, « Pharmaceutical Regulatory Policies in India in The Post-Liberalization Period: A Brief Overview », Indian Journal of Applied Research, En ligne : http://worldwidejournals.in/ojs/index.php/ijar/article/view/4657.
JEFFERY, R., SANTHOSH, M. R., 2009, « Architecture of Drug Regulation in India », Journal of Health Studies, 2009, p. 13.
KALE, D., LITTLE, S., 2007, « From Imitation to Innovation: The Evolution of R&D Capabilities and Learning Processes in the Indian Pharmaceutical Industry », Technology Analysis & Strategic Management, vol. 19, n° 5, p. 589‑609.
KENNEDY, L., 2014, The politics of economic restructuring in India: economic governance and state spatial rescaling, London ; New York, Routledge, Taylor & Francis Group.
KENNEDY, L., 2015, « Stratégies spatiales de l’État en Inde. Le réétalonnage de l’État au travers de la politique des zones franches », EchoGéo, En ligne : http://echogeo.revues.org/14257.
KHATRI, S. D., SAHU, R. K., 2009, « The WTO and India’s Pharmaceutical Industry (Patent Protection, TRIPS, and Developing Countries) », Journal of Pharmacy & Pharmaceutical Sciences, vol. 12, n° 2, p. 229‑231.
LANDY, F., CHAUDHURI, B., 2002, « Introduction », in F. Landy & B. Chaudhuri (Éd.), De la mondialisation au développement local en Inde: questions d’échelles, Collection Monde indien, sciences sociales 15e-20e siècle, Paris, CNRS, p. 7‑21
LANTENOIS, C., CORIAT, B., 2014, « La «préqualification» OMS: origines, déploiement et impacts sur la disponibilité des antirétroviraux dans les pays du Sud », Sciences sociales et santé, vol. 32, n° 1, p. 71‑99.
LEVENSTEIN, M. C., 2003, « Price Wars and the Stability of Collusion: A Study of the Pre-World War I Bromine Industry », The Journal of Industrial Economics, vol. 45, n° 2, p. 117‑137.
LIEFFERS, C., 2016, « Patents, profit and the public good: the case of a 19th-century artificial limb manufacturer », CMAJ, vol. 188, n° 11, p. 824‑825.
LÖFGREN, H., 2007, « The global biopharma industry and the rise of Indian drug multinationals: implications for Australian generics policy », Australia and New Zealand Health Policy, vol. 4, n° 1, p. 10.
MALHOTRA, P., 2010, Impact of TRIPS in India: An Access to medicines perspective, Springer.
MUELLER, J. M., 2006, « The tiger awakens: the tumultuous transformation of India’s patent system and the rise of Indian pharmaceutical innovation », U. Pitt. l. reV., vol. 68, p. 491.
ONDERKOVA, H., 2021, Compulsory Licensing in India and changes brought to it by the TRIPS Agreement, European Business & Technology Centre.
PORDIE, L., GAUDILLIERE, J.-P., 2014, « The reformulation regime in drug discovery: Revisiting polyherbals and property rights in the Ayurvedic industry », East Asian Science, Technology and Society: An International Journal, vol. 8, n° 1, p. 57‑79.
POURRAZ, J., 2019, Réguler et produire les médicaments contre le paludisme au Ghana et au Bénin: une affaire d’État? Politiques pharmaceutiques, normes de qualité et marchés de médicaments, PhD Thesis, Paris, EHESS.
PRADHAN, J. P., 2006, Global competitiveness of Indian pharmaceutical industry: trends and strategies, ISID.
PRADHAN, J. P., 2008, « Overcoming innovation limits through outward FDI: The overseas acquisition strategy of Indian pharmaceutical firms », Available at SSRN 1515587, En ligne : http://papers.ssrn.com/sol3/papers.cfm?abstract_id=1515587.
PRADHAN, J. P., 2010, « Strategic asset-seeking activities of emerging multinationals: Perspectives on foreign acquisitions by Indian pharmaceutical MNEs », Organizations and markets in emerging economies, vol. 1, n° 2, p. 9‑31.
QUET, M., 2018a, Impostures pharmaceutiques: Médicaments illicites et luttes pour l’accès à la santé, La Découverte.
QUET, M., 2018b, « Pharmaceutical Capitalism and its Logistics: Access to Hepatitis C Treatment », Theory, Culture & Society, vol. 35, n° 2, p. 67‑89.
QUET, M., PORDIE, L., BOCHATON, A., CHANTAVANICH, S., KIATYING-ANGSULEE, N., LAMY, M., et al., 2018, « Regulation Multiple: Pharmaceutical Trajectories and Modes of Control in the ASEAN », Science, Technology and Society, vol. 23, n° 3, p. 485‑503.
RAJAN, K. S., 2017, Pharmocracy: Value, politics, and knowledge in global biomedicine, Duke University Press.
RAULT-CHODANKAR, Y.-M., 2020, Les petites entreprises pharmaceutiques indiennes, agents d’une globalisation alternative, Université de Paris.
RAULT-CHODANKAR, Y.-M., 2022, « ‘We care… because care is growth’. The low-tech imaginaries of India’s small-scale pharmaceutical enterprises », SSM - Qualitative Research in Health, vol. 2, p. 100144.
RAULT-CHODANKAR, Y.-M., KALE, D., 2022, « ‘Manufacturers without factories’ and economic development in the Global South: India’s pharmaceutical firms », Journal of Economic Geography, p. lbac013.
REZAIE, R., MCGAHAN, A. M., FREW, S. E., DAAR, A. S., SINGER, P. A., 2012, « Emergence of biopharmaceutical innovators in China, India, Brazil, and South Africa as global competitors and collaborators », Health Research Policy and Systems, vol. 10, n° 1, p. 1.
ROOT, H. L., 1998, « A liberal India: The triumph of hope over experience », Asian Survey, vol. 38, n° 5, p. 510‑534.
ROY, V. (Éd.), 2020, « A Crisis for Cures? Tracing Assetization and Value in Biomedical Innovation », in Assetization: Turning Things into Assets in Technoscientific Capitalism, The MIT Press, p. 97‑124
RUET, J., 2015, « Les firmes indiennes dans la production mondiale : Etat, marchés, innovation, et gouvernance du travail », in J.-F. Huchet, X. Richet, & J. Ruet (Éd.), Chine, Inde: les firmes au cœur de l’émergence, Rennes, Presses universitaires de Rennes,
RUPARELIA, S., 2015, « ‘Minimum Government, Maximum Governance’: The Restructuring of Power in Modi’s India », South Asia: Journal of South Asian Studies, vol. 38, n° 4, p. 755‑775.
SEKALALA, S., FORMAN, L., HODGSON, T., MULUMBA, M., NAMYALO-GANAFA, H., MEIER, B. M., 2021, « Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine », BMJ Global Health, vol. 6, n° 7, p. e006169.
SHADLEN, K. C., 2005, « Exchanging development for market access? Deep integration and industrial policy under multilateral and regional-bilateral trade agreements », Review of International Political Economy, vol. 12, n° 5, p. 750‑775.
SHADLEN, K. C., 2007, « The Political Economy of AIDS Treatment: Intellectual Property and the Transformation of Generic Supply », International Studies Quarterly, vol. 51, n° 3, p. 559‑581.
SIDDIQUI, K., 2010, « Globalisation and neo-liberal economic reforms in India: A critical review », in Prentice Hall India,
SRIVASTAVA, D., 2008, A country level report on the pharmaceutical sector in India part one: Institutions involved in pharmaceutical regulation, London, UK, Department for International Development.
SULIS, G., PRADHAN, R., KOTWANI, A., GANDRA, S., 2022, « India’s ban on antimicrobial fixed-dose combinations: winning the battle, losing the war? », Journal of Pharmaceutical Policy and Practice, vol. 15, n° 1, p. 33.
TIETZE, F., VIMALNATH, P., ARISTODEMOU, L., MOLLOY, J., 2022, « Crisis-Critical Intellectual Property: Findings From the COVID-19 Pandemic », IEEE Transactions on Engineering Management, vol. 69, n° 5, p. 2039‑2056.
TOWNSEND, B., 2016, « International medicines governance 1940s to 1970s: lessons for public health », Critical Public Health, vol. 26, n° 4, p. 466‑476.
VAGUET, A., 2015, « L’espace politique des médicaments: Introduction à une problématique globale », L’Espace Politique, En ligne : http://journals.openedition.org/espacepolitique/3534.
VASIREDDY, U., 2015, « Comparison of Guidelines of Indian GMP with WHO GMP », communication au colloque Hyderabad, 31 p.
WALRAS, L., 1874, « Eléments d’économie politique pure ou théorie de la richesse sociale (Elements of Pure Economics, or the theory of social wealth) », Lausanne, Paris, vol. 1899.
WEISSMAN, R., 1996, « Long, Strange Trips: The Pharmaceutical Industry Drive to Harmonize Global Intellectual Property Rules, and the Remaining WTO Legal Alternatives Available to Third World Countries », University of Pennsylvania Journal of International Economic Law, vol. 17, p. 1069.